Omilancor

N/A

Report date: 2025/04/23 15:04:28
NMEFirst In Class

Base Information

Drug NameOmilancor
Drug Alias NameBT-11
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLanC-like protein 2 agonistsInflammation mediator inhibitors
TargetsLanC-like protein 2
Therapy Area/IndicationsCrohn DiseaseColitis, UlcerativeEosinophilic Esophagitis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBosnia and HerzegovinaUnited StatesUkraine +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesLandos Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesNImmune Biopharma IncShanghai LianBio Development Co Ltd
Inactive CompaniesN/A
Active IndicationsColitis, Ulcerative
Inactive IndicationsCrohn DiseaseEosinophilic Esophagitis

Other Information

ATC CodeN/A
Related LinksN/A